Showing results (781-790 of 808) with videos related to

Sort By:
Pageof 81
Cell|January 21, 2014
Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switchPaul Cohen, Julia D Levy, Yingying Zhang, et al.
European Urology Focus|December 12, 2024
Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST TrialTarek Ajami, Hui Yu, Joao G Porto, et al.
The Journal of Urology|June 20, 2025
Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance TrialPedro F S Freitas, Archan Khandekar, Joao G Porto, et al.
The Journal of Biological Chemistry|August 9, 2002
Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymeraseDashyant Dhanak, Kevin J Duffy, Victor K Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2021
Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal AdenocarcinomasJennifer Y Wo, Jeffrey W Clark, Christine E Eyler, et al.
Science Translational Medicine|January 21, 2026
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticityErica M Pimenta, Amanda E Garza, Sabrina Y Camp, et al.
Journal of Medicinal Chemistry|January 5, 2007
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitorsKrista B Goodman, Haifeng Cui, Sarah E Dowdell, et al.
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
The mutagenic forces shaping the genomic landscape of lung cancer in never smokersMarcos Díaz-Gay, Tongwu Zhang, Phuc H Hoang, et al.
Cell Genomics|November 17, 2022
Uncovering novel mutational signatures by <i>de novo</i> extraction with SigProfilerExtractorS M Ashiqul Islam, Marcos Díaz-Gay, Yang Wu, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activityRobert A Stavenger, Haifeng Cui, Sarah E Dowdell, et al.
Pageof 81